Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
The PI3K-Akt-mTOR signaling pathway in human acute myeloid leukemia (AML) cells
I Nepstad, KJ Hatfield, IS Grønningsæter… - International journal of …, 2020 - mdpi.com
Acute myeloid leukemia (AML) is a heterogeneous group of diseases characterized by
uncontrolled proliferation of hematopoietic stem cells in the bone marrow. Malignant cell …
uncontrolled proliferation of hematopoietic stem cells in the bone marrow. Malignant cell …
PI3K signaling in cancer: beyond AKT
The phosphoinositide 3-kinase (PI3K) signaling pathway is one of the most frequently
altered pathways in human cancer and has a critical role in driving tumor initiation and …
altered pathways in human cancer and has a critical role in driving tumor initiation and …
PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives
The protein kinases regulate cellular functions such as transcription, translation,
proliferation, growth and survival by the process of phosphorylation. Over activation of …
proliferation, growth and survival by the process of phosphorylation. Over activation of …
New concepts and mechanisms of platelet activation signaling
Upon blood vessel injury, platelets are exposed to adhesive proteins in the vascular wall
and soluble agonists, which initiate platelet activation, leading to formation of hemostatic …
and soluble agonists, which initiate platelet activation, leading to formation of hemostatic …
Epithelial-to-mesenchymal transition is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C–mutant non–small cell lung cancer
Y Adachi, K Ito, Y Hayashi, R Kimura… - Clinical Cancer …, 2020 - aacrjournals.org
Purpose: KRAS is among the most commonly mutated oncogene in cancer including non–
small cell lung cancer (NSCLC). In early clinical trials, inhibitors targeting G12C-mutant …
small cell lung cancer (NSCLC). In early clinical trials, inhibitors targeting G12C-mutant …
Dual or multi-targeting inhibitors: The next generation anticancer agents
Dual-targeting/Multi-targeting of oncoproteins by a single drug molecule represents an
efficient, logical and alternative approach to drug combinations. An increasing interest in this …
efficient, logical and alternative approach to drug combinations. An increasing interest in this …
Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies
Cardiac hypertrophy can be defined as an increase in heart mass. Pathological cardiac
hypertrophy (heart growth that occurs in settings of disease, eg hypertension) is a key risk …
hypertrophy (heart growth that occurs in settings of disease, eg hypertension) is a key risk …
Molecular and cellular pathways contributing to brain aging
Aging is the leading risk factor for several age-associated diseases such as
neurodegenerative diseases. Understanding the biology of aging mechanisms is essential …
neurodegenerative diseases. Understanding the biology of aging mechanisms is essential …
PIK3CA in cancer: The past 30 years
Almost thirty years ago, PI3K was discovered as a lipid kinase associated with certain
oncoproteins. The first decade of research on PI3K saw the identification, purification and …
oncoproteins. The first decade of research on PI3K saw the identification, purification and …
PI3K-Akt pathway: its functions and alterations in human cancer
M Osaki, M Oshimura, H Ito - Apoptosis, 2004 - Springer
Abstract Phosphatidylinositol-3-kinase (PI3K) is a lipid kinase and generates
phosphatidylinositol-3, 4, 5-trisphosphate (PI (3, 4, 5) P3). PI (3, 4, 5) P3 is a second …
phosphatidylinositol-3, 4, 5-trisphosphate (PI (3, 4, 5) P3). PI (3, 4, 5) P3 is a second …